In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

Check the time stamp on this data. Updated AI-Generated Signals for Biocryst Pharmaceuticals Inc. (BCRX) available here: BCRX. Type a few symbols and Take a Trial. The signals for these will appear ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

64.4% of Immatics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.3% of Immatics shares are held by insiders.

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 21 and set a price target of $10.00.

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total ...

BioCryst Pharmaceuticals projects 2025 ORLADEYO net revenue of $515-$535 million and total revenue of $540-$560 million. BioCryst Pharmaceuticals announced its preliminary unaudited ORLADEYO ...

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB ®) expected to be between $540-$560 million in 2025— —Company achieved ...

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.